FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced the appointment of Christiane Bardroff as Chief Business Officer (CBO), effective June 1, 2026. Bardroff will lead commercial and sales, business insights and intelligence, strategic partnerships and global marketing, reporting directly to President and CEO Lars Petersen.
Bardroff brings more than 18 years of experience and leadership across customer stewardship and biopharmaceutical operations, including process development and small-, mid-, and large-scale manufacturing, quality control, and quality assurance, as well as procurement, automation, and digitalization. Most recently, she was Chief Operating Officer at Rentschler Biopharma SE. Previously, she advanced through roles of increasing responsibility at Teva Biotech and Roche. As a people-first leader, she previously oversaw approximately 1,300 employees with a strong focus on enablement and empowerment. Bardroff will be based in Germany.
“Christiane brings deep operational experience, strong customer understanding, and a proven ability to scale complex biologics organizations. She has delivered reliable results in highly regulated environments while building strong customer partnerships,” said Petersen. “Her leadership will strengthen how we integrate commercial, technical, and partnership capabilities, which is critical as our organization enters this next strategic growth phase.”
Also Read: NanoImaging Services Appoints Fraser McLeod as Chief Executive Officer to Lead Next Phase of Growth
“I am excited to join FUJIFILM Biotechnologies at this important stage in its growth journey,” said Bardroff. “The company combines strong technical capabilities with a people-focused culture and a clear ambition to be a long-term partner across the biopharma landscape. I look forward to working with colleagues and customers across the globe to strengthen partnerships and support delivery of therapies to patients worldwide.”
The appointment reflects FUJIFILM Biotechnologies’ continued evolution to support long-term growth, deepen strategic relationships, and strengthen enterprise-wide alignment as the company expands globally.
Henrik Ernlund, currently serving as interim Chief Commercial Officer, will continue as Head of Global Sales, effective June 1 to ensure continuity for customers and partners.
“We are grateful to Henrik for his leadership these past few months. Looking ahead, I’m excited about having close collaboration between Henrik and Christiane to strengthen the integration between sales, commercial strategy, and execution, and to continue delivering for our customers,” added Petersen.
SOURCE: Businesswire
